Charles Baltic

Président chez Assayquant Technologies, Inc.

Profil

Charles V.
Baltic currently works at AssayQuant Technologies, Inc., as Chairman and SIDIS, Inc., as Executive Vice President from 2019.
Mr. Baltic also formerly worked at Amyndas Pharmaceuticals LLC, as Chief Executive Officer from 2021 to 2022, MEI Pharma, Inc., as Chairman from 2023 to 2024, Cowen & Co. (New York), as Director-Life Science, Wachovia Securities LLC, as Managing Director-Healthcare Investment Banking from 2001 to 2006, Needham & Co. LLC, as Managing Director & Co-Head-Healthcare from 2009 to 2019, CRT Capital Group LLC, as Managing Director from 2006 to 2008, Med-Vantage, Inc., as Director, US Securities & Exchange Commission, as Member from 2013 to 2015, Washington Biotechnology & Biomedical Association, as Trustee from 2013 to 2018, The Hope Funds for Cancer Research, as Founding Trustee from 2007 to 2017, and Sidis Corp, as Chief Operations Officer from 2019 to 2021.
Mr. Baltic received his undergraduate degree and graduate degree from Georgetown University and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.

Postes actifs de Charles Baltic

Sociétés	Poste	Début
SIDIS, Inc.	Corporate Officer/Principal	01/01/2019
Assayquant Technologies, Inc.	Président	-

Anciens postes connus de Charles Baltic

Sociétés	Poste	Fin
LITE STRATEGY, INC.	Président	01/08/2024
Amyndas Pharmaceuticals LLC	Directeur Général	01/10/2022
Sidis Corp	Directeur des opérations	01/01/2021
Needham & Co. LLC	Corporate Officer/Principal	01/01/2019
Washington Biotechnology & Biomedical Association	Directeur/Membre du Conseil	01/01/2018